礼来Achieve-3研究:Orforglipron在主要及所有关键次要终点上均优于口服司美格鲁肽

美股速递
Feb 26

在礼来公司公布的Achieve-3临床研究结果中,其药物Orforglipron表现卓越,不仅达到了主要研究终点,更在所有关键次要终点上显著超越了口服司美格鲁肽。这一积极数据进一步验证了Orforglipron的治疗潜力。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10